

Supplemental Table 3. Pirtobrutinib therapy, PD, post PD therapy, and current cycle for patients on therapy

Pt # for ms	DISEASE	Sex	Age at entry	ECOG	Best reponse	Cycle to best	Status as of June 2023	Therapy post pirtobrutinib or pirtobrutinib cycle
1	CLL	M	82	0	PR	12	PD	PKC-beta inhibitor; Ven + Obin
2	CLL	M	71	1	PR	9	PD	Lost to Follow-up
3	CLL	M	55	0	PR	5	PD	PKC-beta inhibitor
4	CLL	M	75	0	PR	1	PD	Ven + Obin
5	CLL	M	69	1	PR	2	PD	Ibr + CAR-T; Ven + Obin
6	CLL	F	66	1	PR	4	PD	Ibr + CAR-T
7	CLL	M	78	0	PR	2	PD	Lost to Follow-up
8	CLL	F	75	1	PR	1	PD	Ven + Obin
9	CLL	F	75	1	PR	2	PD	Ibr + Ven; Zanu + Ven
10	CLL	M	64	0	PR	2	PD	PKC-beta inhibitor; Ibr + Ven
11	CLL	M	63	1	PR	4	PD	Zanu + Ven + Obin
12	CLL	F	61	1	PR	3	PD -RT	Nivolumab + Ibr; RCHOP + Ven; Allo-SCT
13	CLL	M	63	1	PR	4	PD	Acala + Ven
14	CLL	F	59	0	PR	3	PD	Acala + Ven + Obin; Allo-SCT
15	CLL	M	87	2	PR	2	On Rx	C37
16	CLL	M	58	1	PR	4	On Rx	C31
17	CLL	M	64	0	PR	4	On Rx	C34
18	CLL	M	79	0	PR	2	On Rx	C34
19	CLL	M	74	1	PR	2	On Rx	C31
20	CLL	M	71	1	PR	2	On Rx	C30
21	CLL	F	70	1	PR	3	On Rx	C31
22	CLL	F	82	0	PR	2	On Rx	C30
23	CLL	M	75	0	PR	4	On Rx	C42

Acalabrutinib, acalabrutinib; Ven, venetoclax; Ibr, Ibrutinib; Obin, obinutuzumab; PR, partial response; PD, disease progression; PD-RT, progressive disease Richter's transformation; On Rx, on therapy; C, cycle; Zanu, zanubrutinib; SCT, stem cell transplant